Navigation Links
Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris
Date:5/18/2011

CHAPEL HILL, N.C., May 18, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at two upcoming investor conferences in Paris.  Dr. Fernandes will present at the 18th Annual Euro-Biotech Forum at 9:45 a.m. CET, May 24, at the Hilton Arc de Triomphe.  Dr. Fernandes will later present at BioEquity Europe 2011 at 3:00 p.m. CET, May 24, at the Paris Marriott Rive Gauche.  Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin for community-acquired bacterial pneumonia and TAKSTA™ for the oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA).

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially and medically differentiated and novel products that reduce development risk and provide a high financial return. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.

Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
Robert.flamm@russopartnersllc.com

Tony Russo, Ph.D.
Russo Partners, LLC
(212) 845-4251
Tony.russo@russopartnersllc.com


'/>"/>
SOURCE Cempra Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intravenous (IV) Administration of Cempra Pharmaceuticals Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
2. Cempra Pharmaceuticals to Present at Two Upcoming Cambridge Healthtech Institute (CHI) Conferences
3. Cempra Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™
5. Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
6. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
7. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
8. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
9. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
10. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
11. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... VANCOUVER, British Columbia , March 23, 2017 ... (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical company ... today announced that data from its successful Phase 2a ... focal treatment for localized prostate cancer, will be presented ... 32 nd Annual European Association of Urology in ...
(Date:3/23/2017)...  Interpace Diagnostics Group, Inc. (NASDAQ: ... company that provides clinically useful molecular diagnostic tests ... entered into agreements to successfully restructure its secured ... concurrently terminate its royalty and milestone obligations. ... RedPath amounting to $9.34 million is being acquired ...
(Date:3/23/2017)... , March 23, 2017  Drug diversion is ... misuse and deadly overdoses. A new oral fluid ... www.cordantsolutions.com , reports more detailed and actionable ... can potentially improve therapy adherence, patient safety, and ... Cordant Comprehensive Oral fluid Rx Evaluation (CORE) system ...
Breaking Medicine Technology:
(Date:3/23/2017)... , ... March 23, 2017 , ... ... families and businesses of the greater Fort Collins area, has unveiled a collaboration ... ongoing community involvement program. Donations to this worthy cause may now be made ...
(Date:3/23/2017)... ... March 23, 2017 , ... ?This conference will prominently feature 150+ Hospital and Health System Executive ... Healthcare: Susan Salka , 43rd President of the United States of America: George ... Life In and Out of the Ring: Sugar Ray Leonard , JD, Chairperson, ...
(Date:3/23/2017)... Raton, FL (PRWEB) , ... March 23, 2017 ... ... of dietary supplements that help improve all aspects of people’s health and nutrition, ... website for nutritional products. , Natural Subsistence develops nutritional supplements that help ...
(Date:3/23/2017)... ... , ... The American Board of Quality Assurance and Utilization Review Physicians (ABQAURP) ... Health Care Quality and Management and Patient Safety. , It is with appreciation and ... also to the Health Care Quality and Patient Safety movements. Diplomates and Members lead ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Guidelines and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, ...                  , How will the new EU MDR language change the way ...
Breaking Medicine News(10 mins):